Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas G McNeel

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 20, 2007
Cellular immunotherapies for prostate cancerDouglas G McNeel
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Prostate cancer antigens and vaccines, preclinical developmentsDouglas G McNeel
Journal for Immunotherapy of Cancer|November 24, 2016
TCR diversity - a universal cancer immunotherapy biomarker?Douglas G McNeel
Current Opinion in Urology|April 7, 2007
Prostate cancer immunotherapyDouglas G McNeel
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 30, 2017
Therapeutic Cancer Vaccines: How Much Closer Are We?Douglas G McNeel
Immunology Letters|December 9, 2004
Immune-based therapies for prostate cancerDouglas G McNeel, Miroslav Malkovsky
Oncoimmunology|March 28, 2022
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expressionDonghwan Jeon, Douglas G McNeel
Oncoimmunology|May 19, 2023
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNAIchwaku Rastogi, Douglas G McNeel
Expert Review of Vaccines|July 14, 2010
DNA vaccines for the treatment of prostate cancerSheeba Alam, Douglas G McNeel
Endocrine-Related Cancer|August 18, 2017
Androgen deprivation and immunotherapy for the treatment of prostate cancerMelissa Gamat, Douglas G McNeel
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 20, 2007
Cellular immunotherapies for prostate cancerDouglas G McNeel
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Prostate cancer antigens and vaccines, preclinical developmentsDouglas G McNeel
Journal for Immunotherapy of Cancer|November 24, 2016
TCR diversity - a universal cancer immunotherapy biomarker?Douglas G McNeel
Current Opinion in Urology|April 7, 2007
Prostate cancer immunotherapyDouglas G McNeel
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 30, 2017
Therapeutic Cancer Vaccines: How Much Closer Are We?Douglas G McNeel
Immunology Letters|December 9, 2004
Immune-based therapies for prostate cancerDouglas G McNeel, Miroslav Malkovsky
Oncoimmunology|March 28, 2022
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expressionDonghwan Jeon, Douglas G McNeel
Oncoimmunology|May 19, 2023
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNAIchwaku Rastogi, Douglas G McNeel
Expert Review of Vaccines|July 14, 2010
DNA vaccines for the treatment of prostate cancerSheeba Alam, Douglas G McNeel
Endocrine-Related Cancer|August 18, 2017
Androgen deprivation and immunotherapy for the treatment of prostate cancerMelissa Gamat, Douglas G McNeel
Pageof 14